Literature DB >> 25961323

A Note of Caution on the Role of Halogen Bonds for Protein Kinase/Inhibitor Recognition Suggested by High- And Low-Salt CK2α Complex Structures.

Barbara Guerra1, Nils Bischoff2, Volodymyr G Bdzhola3, Sergiy M Yarmoluk3, Olaf-Georg Issinger1, Andriy G Golub3, Karsten Niefind2.   

Abstract

CK2 is a Ser/Thr kinase recruited by tumor cells to avoid cell death. 4'-Carboxy-6,8-dibromo-flavonol (FLC26) is a nanomolar CK2 inhibitor reducing the physiological phosphorylation of CK2 biomarkers and inducing cell death. Its binding mode to the ATP site was predicted to depend primarily on noncovalent interactions not comprising halogen bonds. We confirm this by two independent cocrystal structures which additionally show that FLC26 is selective for an open, protein kinase-untypical conformation of the hinge/helix αD region. The structures suggest how the bromo substituents, found previously in lead optimization studies, contribute to the inhibitory efficacy. In this context, one of the complex structures, obtained by crystallization with the kosmotropic salt NaCl, revealed an unconventional π-halogen bond between the 8-bromo substituent of FLC26 and an aromatic side chain which is absent under low-salt conditions. The kosmotropic salt sensitivity of π-halogen bonds is a novel feature which requires attention in structural comparisons and halogen-bond-based explanations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961323     DOI: 10.1021/acschembio.5b00235

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  7 in total

1.  2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.

Authors:  Benoît Bestgen; Isabelle Krimm; Irina Kufareva; Ahmed Ashraf Moustafa Kamal; Wei-Guang Seetoh; Chris Abell; Rolf W Hartmann; Ruben Abagyan; Claude Cochet; Marc Le Borgne; Matthias Engel; Thierry Lomberget
Journal:  J Med Chem       Date:  2019-02-18       Impact factor: 7.446

2.  2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.

Authors:  Benoît Bestgen; Irina Kufareva; Weiguang Seetoh; Chris Abell; Rolf W Hartmann; Ruben Abagyan; Marc Le Borgne; Odile Filhol; Claude Cochet; Thierry Lomberget; Matthias Engel
Journal:  J Med Chem       Date:  2019-02-13       Impact factor: 7.446

3.  Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Authors:  Paul Brear; Darby Ball; Katherine Stott; Sheena D'Arcy; Marko Hyvönen
Journal:  J Med Chem       Date:  2020-10-29       Impact factor: 7.446

4.  Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'.

Authors:  Jennifer Hochscherf; Dirk Lindenblatt; Benedict Witulski; Robin Birus; Dagmar Aichele; Christelle Marminon; Zouhair Bouaziz; Marc Le Borgne; Joachim Jose; Karsten Niefind
Journal:  Pharmaceuticals (Basel)       Date:  2017-12-13

5.  Specific inhibition of CK2α from an anchor outside the active site.

Authors:  Paul Brear; Claudia De Fusco; Kathy Hadje Georgiou; Nicola J Francis-Newton; Christopher J Stubbs; Hannah F Sore; Ashok R Venkitaraman; Chris Abell; David R Spring; Marko Hyvönen
Journal:  Chem Sci       Date:  2016-07-12       Impact factor: 9.825

6.  Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor.

Authors:  Karsten Niefind; Nils Bischoff; Andriy G Golub; Volodymyr G Bdzhola; Anatoliy O Balanda; Andriy O Prykhod'ko; Sergiy M Yarmoluk
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-11

7.  A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors.

Authors:  Alexander Schnitzler; Andreas Gratz; Andre Bollacke; Michael Weyrich; Uwe Kuckländer; Bernhard Wünsch; Claudia Götz; Karsten Niefind; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.